
Office:
LSUHSC School of Medicine
533 Bolivar Street, CSRB 547
New Orleans, LA 70112
504-568-7027
Bio
Dr. Giulia Monticone received her B.S. and M.S. at the University of Pavia (Italy), studying signaling pathways involved in cancer biology, followed by a Ph.D. from the University of Manchester (UK), where she investigated the post-translational regulation of intracellular signaling networks relevant to cancer progression and immune regulation. She completed her postdoctoral training at LSU Health Sciences Center, specializing in immunosuppression and immunotherapy in the context of cancer and infections.
As an Assistant Professor, Dr. Monticone leads a research program focused on: (1) Mechanisms of immunosuppression in cancer, infection, and other immune-related disorders; (2) Computational drug discovery for immunotherapy; (3) Development of 3D organoid models to study immunoregulation and pre-clinical drug testing.
Her work is supported by independent funding, including awards from the Department of Defense (DOD) and the Center for Clinical and Translational Science (CCTS).
Education
Ph.D. in Developmental Biology, The University of Manchester, United Kingdom
M.S. in Molecular Biology and Genetics, University of Pavia, Italy
B.S. in Biotechnology, University of Piemonte Orientale “Amedeo Avogadro”, Italy
Teaching
Lecturer, BIOMED 130, Techniques & Trends in Biomedical Sciences
Lecturer, ONCO206, Signal Transduction and Metabolism in Cancer
Publications
Selected publications
King, B., Huang, Z., Hewins, P., Cook, T., Mirzalieva, O., Larter, K., Wyczechowska, D., Crabtree, J., Garai, J., Li, L., Zabaleta, J., Barbier, M., Del Valle, L., Jurado, K., Miele, L. and Monticone, G. (2024) Adenosine analogs have immunomodulatory antiviral properties through the Adenosine A2A Receptor pathway, The Journal of Immunology, Volume 212, Issue 1_Supplement, Page 1299_4492, https://doi.org/10.4049/jimmunol.212.supp.1299.4492
Monticone, G.*, Huang, Z., Hewins, P., Cook, T., Mirzalieva, O., King, B., Larter, K., Miller-Ensminger, T., Sanchez-Pino, M. D., Foster, T. P., Nichols, O. V., Ramsay, A. J., Majumder, S., Wyczechowska, D., Tauzier, D., Gravois, E., Crabtree, J. S., Garai, J., Li, L., Zabaleta, J., … Miele, L. (2024). Novel immunomodulatory properties of adenosine analogs promote their antiviral activity against SARS-CoV-2. EMBO reports, 25(8), 3547–3573. https://doi.org/10.1038/s44319-024-00189-4 *First and corresponding author
Monticone, G., Huang, Z., Csibi, F., Leit, S., Ciccone, D., Champhekar, A. S., Austin, J. E., Ucar, D. A., Hossain, F., Ibba, S. V., Boulares, A. H., Carpino, N., Xu, K., Majumder, S., Osborne, B. A., Loh, C., & Miele, L. (2022). Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses. Frontiers in immunology, 13, 987298. https://doi.org/10.3389/fimmu.2022.987298
Monticone, G., & Miele, L. (2021). Notch Pathway: A Journey from Notching Phenotypes to Cancer Immunotherapy. Advances in experimental medicine and biology, 1287, 201–222. https://doi.org/10.1007/978-3-030-55031-8_13
Research
Our research focuses on reversing disease-induced immunosuppression to restore protective immune responses and improve outcomes in cancer, infections and other immune-related conditions. https://sites.google.com/view/monticone-giulia-lab/home
Mechanisms of immunosuppression
Our group has identified the Cbl-b-Notch1 axis as a critical regulatory mechanism of immunosuppression in T cells and other immune components, during infections and in the tumor microenvironment. By dissecting the molecular mechanisms of this axis, we aim to uncover how it dampens protective immunity and contributes to disease progression.
Our goal is to target this pathway therapeutically to restore immune function in cancer and infections, and understand its regulation to fine-tune immune responses. This project bridges basic immunology with translational potential, offering a promising direction for novel immunotherapies.
Computational drug discovery for immunotherapy
We are developing dual-functional small molecules that modulate the immune system to restore host defense. These compounds are designed to simultaneously target infectious agents or cancer cells and overcome immunosuppression, offering a powerful strategy for treating complex diseases such as viral infections and cancer.
We have trained an AI-driven predictive model using experimental and literature-derived data to identify candidate molecules with dual immunomodulatory activity. We are leveraging this platform to design next-generation immunotherapeutics.
This project combines computational drug discovery, immunology, and translational pharmacology to pioneer a new class of broad-spectrum, immune-restorative therapies.
3D Organoid models
Our lab is developing advanced organoid-based models to mimic tissue microenvironments for the study of mechanisms of immunosuppression and preclinical testing of novel immunotherapies. These 3D models provide a physiologically relevant platform to investigate how immune cells interact in complex tissue settings.